The drug discovery division further expands the CDMOs breadth of services to the biotech industry and complements its fully-connected continuous manufacturing platform (EnzeneX)-equipped biologics manufacturing site, which will open later this summer in the U.S.

Enzene is launching a new Discovery Division at its Pune facility to meet increasing industry demands. This division will offer integrated discovery services, including antibody services, reagent production, and multi-platform assays. The state-of-the-art laboratories are expected to be operational by July, with further expansions planned later in the year.

By integrating its existing capabilities in bioprocessing, product development, and commercialization with its new discovery capabilities, Enzene will be a one-stop solution provider.

“There is a global shortage of biology services, and our clients are increasingly looking to collaborate with us much earlier in the discovery phase to expedite their progress to IND and beyond," commented Himanshu Gadgil, CEO of Enzene Biosciences. "For our big pharma partners, in addition to running the integrated programs, we provide the flexibility to easily outsource non-core activities. In particular, we have seen strong demand for high quality reagents and assay services that play a crucial role across drug discovery and development.”